ETN101

ETN101 is a novel oral small molecule multiple tyrosine kinase inhibitor (mTKI) developed by Etnova Therapeutics for the treatment of advanced hepatocellular carcinoma (HCC). It targets several key receptor tyrosine kinases implicated in tumor growth and angiogenesis, including fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase KIT, vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta (PDGFR-beta). Preclinical studies have demonstrated that ETN101 inhibits cancer cell proliferation and survival both in vitro and in vivo. In animal models of HCC—including those resistant to standard therapies such as sorafenib and lenvatinib—ETN101 induced significant tumor regression or complete remission. Mechanistically, it blocks angiogenesis-related signaling via VEGFR2 inhibition and modulates the tumor microenvironment by regulating the Wnt/β-catenin pathway, increasing cytotoxic T cell infiltration into tumors. The drug is currently being evaluated in phase 1 clinical trials for safety, tolerability, pharmacokinetics, and efficacy in patients with advanced HCC who have failed prior lines of therapy[1][2][5][6][8].